Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Selara (Drug)
Phase: N/A
Status: Completed
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
To collect the efficacy and safety information of Eplerenone on patients with hypertension
related to their appropriate use in daily practice.
Clinical Details
Official title: Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: Number of Participants With Treatment Related Adverse Events.Number of Participants With Serious Treatment Related Adverse Events.
Secondary outcome: Change in Systolic Blood Pressure Over Time.Change in Diastolic Blood Pressure Over Time. Number of Participants That Responded to Selara Treatment.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male or Female patients who are prescribed Selara tablet for Hypertension.
Exclusion Criteria:
- Subjects who have been prescribed Selara tablet.
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: June 2008
Last updated: November 20, 2013
|